Clinical Trial

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL. This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-26; most recent amendment 2026-06-18.
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT07154264
Lead Sponsor Dizal Pharmaceuticals
Conditions Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment 66 participants
Start Date 2025-09-22
Primary Completion 2029-12 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-22